Unexplained Recurrent Pregnancy Loss: New Therapeutic Perspectives
NCT ID: NCT06867900
Last Updated: 2025-03-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
NA
22 participants
INTERVENTIONAL
2021-01-01
2025-07-06
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Cohort of Patients Presenting Unexplained Recurrent Miscarriages and Identification of Early Miscarriage Recidivism Factors
NCT05557201
Live Birth Rate in Patients With Unexplained Recurrent Pregnancy Loss
NCT04621773
Genomics and Microbiome Investigation in Cases of Recurrent Pregnancy Losses
NCT06604338
Incidence of Early Pregnancy Loss in Patients With Unexplained Infertility
NCT01015690
The Novel Immunomodulatory and Anticoagulant Therapies for Recurrent Pregnancy Loss
NCT02990403
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Bifidobacterium Longum
Bifidobacterium Longum ES1
Oral administration of Bifidobacterium Longum ES1 for three months.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Bifidobacterium Longum ES1
Oral administration of Bifidobacterium Longum ES1 for three months.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Genetic predisposition to celiac disease
Exclusion Criteria
18 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Chiara Tersigni
Role: PRINCIPAL_INVESTIGATOR
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Reasearch Laboratory 3J IRCCS Gemelli
Rome, , Italy
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1355
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.